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results with the severity of the clinical and immunologic phenotype.
Methods: Abelson virus-transformed Rag2
2/2 pro-B cells engineered to contain an inverted green fluorescent protein (GFP) cassette flanked by recombination signal sequences were transduced with retroviruses encoding either wild-type or 41 naturally occurring RAG2 variants. Bicistronic vectors were used to introduce compound heterozygous RAG2 variants. The percentage of GFP-expressing cells was evaluated by using flow cytometry, and high-throughput sequencing was used to analyze rearrangements at the endogenous immunoglobulin heavy chain (Igh) locus. Results: The RAG2 variants showed a wide range of recombination activity. Mutations associated with severe combined immunodeficiency and Omenn syndrome had significantly lower activity than those detected in patients with less severe clinical presentations. Four variants (P253R, F386L, N474S, and M502V) previously thought to be pathogenic were found to have wild-type levels of activity. Use of bicistronic vectors permitted us to assess more carefully the effect of compound heterozygous mutations, with good correlation between GFP expression and the number and diversity of Igh rearrangements. Conclusions: Our data support genotype-phenotype correlation in the setting of RAG2 deficiency. The assay described can be used to define the possible disease-causing role of novel RAG2 variants and might help predict the severity of the clinical phenotype. (J Allergy Clin Immunol 2019;143:726-35.)
Key words: Recombination-activating gene 2, VDJ recombination, severe combined immunodeficiency, Omenn syndrome, autoimmunity, genotype-phenotype correlation Recombination-activating gene (RAG) 1 and RAG2 proteins initiate the VDJ recombination process, allowing generation of T and B lymphocytes with a largely diversified repertoire of antigen receptor specificities (reviewed by Notarangelo et al 1 ) . In particular, RAG1 and RAG2 form a heterotetrameric complex that binds to the recombination signal sequences flanking each of the variable (V), diversity (D) and joining (J) gene segments and introduces double-strand DNA breaks that are sealed by hairpins. On opening of the hairpin by ARTEMIS, proteins of the nonhomologous end-joining machinery complete the VDJ recombination process by mediating joining of the coding ends and formation of signal joins. 1 Mutations of the RAG1 and RAG2 genes in human subjects are associated with a broad range of clinical and immunologic phenotypes, including severe combined immunodeficiency (SCID) with absence of T and B lymphocytes (T 2 B 2 SCID), 2 Omenn syndrome (OS), 3 atypical severe combined immunodeficiency (AS), 4 combined immunodeficiency with granulomas and/or autoimmunity (CID-G/AI), 5 and other milder presentations. We have reported previously on a flow cytometry-based assay in which Abelson virus (v-Abl)-transformed Rag1 2/2 pro-B cells engineered to contain an inverted green fluorescent protein (GFP) cassette flanked by recombination signal sequences (pMX-INV) were transduced with retroviruses encoding either a wild-type (WT) or a mutant human RAG1 protein. 6 In this assay, because the Rag1 2/2 pro-B cells express both RAG2 and the components of the nonhomologous end-joining machinery, the proportion of GFP 1 cells can be used to measure the recombinase activity of the introduced human RAG1 protein. The results obtained supported correlation between levels of recombination activity of the mutant RAG1 proteins and the severity of the clinical and immunologic phenotype observed in patients with RAG1 deficiency. 6 Here, using a similar assay based on a v-Abl Rag2 2/2 pro-Bcell line containing a single pMX-INV integrated cassette, we report on the systematic analysis of recombination activity of 41 naturally occurring human RAG2 variant proteins (including compound heterozygous variants) identified in 58 patients with various clinical and immunologic phenotypes. Our results demonstrate that genotype-phenotype correlation also exists for patients with RAG2 deficiency. Therefore this assay might be useful in determining the pathogenicity of newly identified RAG2 mutations.
METHODS Patients
Deidentified clinical, molecular, and immunologic data of patients with RAG2 mutations were collected both by means of literature search and through collaboration with referring clinicians. The study was approved by the Institutional Review Board at Boston Children's Hospital and at local institutions of the referring physicians and was conducted according to protocol 16-I-N139 approved by the National Institutes of Health Institutional Review Board.
Analysis of recombination activity
The v-Abl Rag2 2/2 Em-Bcl2 pro-B-cell line with a pMX-INV and human truncated hCD4 cassette was generated by transducing v-Abl Rag2 2/2 pro-B cells with a retrovirus containing the pMX-INV-internal ribosome entry site (IRES)-hCD4 plasmid, as previously described. 7, 8 Cells with successful integration of the pMX-INV-IRES-hCD4 cassette express a truncated human CD4 surface protein, allowing for selection by using anti-hCD4 magnetic beads (MACS; Miltenyi Biotech, Bergisch Gladbach, Germany). The hCD4-enriched cells were further transduced with a retrovirus containing either the pBMN-WT-hRAG2-IRES-hCD2 or pBMN-Mut-hRAG2-IRES-hCD2 plasmid expressing WT or mutant (Mut) human RAG2 (hRAG2) protein, respectively. In parallel, Rag2 High-throughput sequencing analysis of rearrangements at the endogenous immunoglobulin heavy chain locus
Analysis of immunoglobulin heavy chain (Igh) locus rearrangements in transduced Rag2
2/2 v-Abl pro-B cells was performed by Adaptive Biotechnologies (Seattle, Wash), as described previously. 9 Sequences were aligned to a reference genome, and Igh VDJ gene definitions were based on ImMunoGeneTics system (see Table E1 in this article's Online Repository at www. jacionline.org). 10 These sequences are available in Table E1 . Heat maps were generated to detail the frequency of individual V-J rearrangements within unique sequences of rearrangement products. The Shannon diversity index and Simpson index were calculated by using the PAST program, as described previously, 11 and according to the following formulas:
where R indicates total templates, i indicates unique rearrangements, p i indicates the proportion of the total sequences belonging to the ith unique rearrangement, and D indicates dominance and unevenness.
In particular, the Simpson D index takes into account both richness and evenness. With this index, 0 represents infinite diversity, and 1 indicates no diversity.
Statistical analysis
Statistical analyses for 1-way ANOVA for nonparametric analysis (Kruskal-Wallis) and post hoc analysis of the unpaired, 1-tailed, nonparametric Mann-Whitney test were carried out with Prism 5 software (GraphPad, La Jolla, Calif).
RESULTS

Patients' clinical and molecular features
We compiled a list of 58 RAG2-deficient patients from published manuscripts and unpublished sources. These patients were divided into 4 different groups based on their clinical and immunologic presentation and according to the diagnostic criteria of the Primary Immunodeficiency Treatment Consortium. 12 In particular, 20 patients were given a diagnosis of T 2 B 2 SCID, 2,4,13-21 28 patients were given a diagnosis of OS, 2,4,14-19,22-27 7 patients were given a diagnosis of AS, 26,28 and 3 patients were given a diagnosis of CID-G/AI (Table I) . 2, 4, 5, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Analysis of the distribution of RAG2 mutations by disease phenotype revealed that some mutations were observed in multiple patients with the same phenotype, such as p.G35A, which was reported in 4 patients with AS, and the p.C478Y mutation, which was detected in 3 patients with SCID. Moreover, 6 other mutations (G95R, K127X, M285R, G451A, W453R, and E480X) were identified in 2 patients each, with the same clinical phenotype (Fig 1) . Missense mutations at residues G35, T215, and R229 were identified in 24 patients who presented with either SCID or OS, indicating that these mutations are associated with a severe but somewhat variable phenotype. Furthermore, missense mutations at residues R73 and M459 were reported in patients with either OS or AS. By contrast, other mutations (F62L, T77N, and G451A) were reported only in patients with CID-G/AI (Fig 1) .
Distribution and recombination activity of mutant RAG2 proteins
As a preliminary step to analyze the recombination activity of the RAG2 variants identified in the patients, we transduced murine Rag2 2/2 Abl pro-B cells with a vector encoding for either human or mouse WT RAG2 (WT-hRAG2 and WT-mRAG2) or with an empty vector and compared levels of GFP expression on treatment with STI-571 (Fig 2, A) . As shown in Fig 2, B , similar levels of GFP expression were induced by hRAG2 and mRAG2, whereas no GFP expression was observed in cells transduced with an empty vector (Fig 2, B) . Altogether, these data Age, Age at presentation; AIHA, autoimmune hemolytic anemia; ALC, absolute lymphocyte count; APS, antiphospholipid syndrome; ARDS, acute respiratory distress syndrome; BCGitis, systemic dissemination of the attenuated Mycobacterium bovis bacillus of the tuberculosis vaccine; CMV, cytomegalovirus; DIC, disseminated intravascular coagulation; IBD, inflammatory bowel disease; ITP, immune thrombocytopenic purpura; LAD, lymphadenopathy; NA, not available; N, normal; PJP, Pneumocystis jirovecii pneumonia; RSV, respiratory syncytial virus; URTI, urinary tract infection. *Maternal.
Maternal engraftment.
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indicate that hWT-RAG2 can cooperate efficiently with mWT-RAG1 in mediating recombination. Initially, Rag2 2/2 Abl pro-B cells were transduced with vectors encoding for various RAG2 mutant proteins (C478Y, A456T, W416L, and G451A) that had been identified in patients with SCID, OS, OS, and CID-G/AI, respectively. As shown in Fig 2, B , no detectable levels of GFP expression were induced by the C478Y mutant protein, whereas the G451A mutant protein supported significant levels of GFP expression, although levels were lower than in the presence of hWT-RAG2. Finally, low but detectable levels of GFP expression were supported by the A456T and W416L mutant proteins associated with OS (Fig 2, B) .
Based on these data, we performed a comprehensive analysis of the recombinase activity of 41 naturally occurring RAG2 mutations, including 31 for which no data of functional activity had been reported previously. Among the 41 mutations tested, 6 were nonsense mutations, and the remaining 35 were missense mutations. Both the nonsense and missense mutations were distributed broadly along the length of the hRAG2 protein (Fig 3, A, and Table II) . A higher density of mutations was observed in the plant homology domain at the C-terminus of the molecule, where mutations affected 18% of the amino acids included in the region compared with 6% and 3% of the amino acids being targeted by mutations in the core and acidic regions of RAG2, respectively (Fig 3, B) . Although the 6 nonsense mutations supported no or minimal levels of recombination (range, 0.1% to 2.9% of WT-hRAG2), variable levels of functional activity could be ascribed to the 35 missense mutations (mean, 25.2% [range, 0.2% to 109.1%] of WT-hRAG2; Fig 3, C) . Overall, missense variants supported significantly greater recombination activity than nonsense variants (P <.01; Fig 3, C) . Finally, no clear difference of functional activity was observed for mutations affecting the plant homology domain or other domains of the protein (Fig 3, D) . Interestingly, among the 41 RAG2 variants tested, 4 (P253R, F386L, N474S, and M502V) showed levels of recombination activity comparable with that associated with hWT-RAG2 (Table II) .
For all of the RAG2 variants tested, we reported their minor allele frequency (MAF) in the Genome Aggregation Consortium (gnomAD) database, 29 which calculated the combined annotation-dependent depletion (CADD)2PHRED score 30 to predict deleteriousness and incorporated these data and the results of functional analysis of recombination activity in a scheme to assess pathogenicity according to guidelines of the American College of Medical Genetics and Genomics. 31 We reported in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) all the variants studied here (see Table E2 in this article's Online Repository at www.jacionline.org).
Correlation of the recombination activity of mutant RAG2 proteins with clinical phenotype
On excluding 3 patients whose RAG2 mutant proteins (P253R, N474S, and M502V) supported WT levels of recombination activity, we aimed to determine whether the mean recombination activity of the mutant alleles identified in the remaining 55 patients correlated with the severity of the clinical phenotype. As shown in Fig 4, mutations associated with SCID and OS allowed similar levels of recombination activity, which were significantly lower than those identified in patients with the AS and CID-G/AI phenotypes. Although only a few patients with CID-G/AI were included in this study, these data support the notion that genotype-phenotype correlation exists also for human RAG2 deficiency, as previously found for RAG1 deficiency. 6 
Analysis of recombination activity of compound heterozygous RAG2 variants
Among the 58 patients, 16 were compound heterozygous for 15 distinct combinations involving a total of 21 distinct RAG2 (Table I ). In several of these cases, the 2 RAG2 alleles supported markedly different levels of recombination activity, making it difficult to predict the net effect of the compound heterozygous RAG2 variants on V(D)J recombination.
Furthermore, the RAG complex is expressed as a heterotetramer including 2 molecules each of RAG1 and RAG2, so that the simultaneous presence of 2 distinct RAG2 variants in the complex might have very different effects than 2 copies of each variant alone. To investigate this in greater detail, we generated bicistronic retroviral vectors expressing equimolar amounts of 2 distinct RAG2 cDNA variants and did this for 5 cases of compound heterozygous variants that had been identified in patients P2, P9, P12, P44, and P45 included in this study. In parallel, a bicistronic vector expressing 2 copies of hWT-RAG2 was also generated. Analysis of the recombination activity supported by the bicistronic vectors produced results that were not easily predictable based on the activity of each individual variant (Fig 5,  A) . For example, P44 was compound heterozygous for 2 variants (T251I and R229Q) that supported 67.2% and 8.9% WT recombination activity, respectively. The bicistronic vector including both variants allowed levels of recombination activity (63%) that were very similar to those of the allele with higher residual function. By contrast, P9 was compound heterozygous for the G35A and E437K variants, which supported 22.1% and 0.9% recombination activity, respectively, whereas the bicistronic vector expressing both of these variants yielded levels of recombination activity (3.9%) that were similar to the less functional allele.
Next, we studied the richness and diversity of V-D-J rearrangements introduced by the bicistronic vectors at the endogenous Igh locus in Rag2 2/2 v-Abl pro-B cells. As shown in Fig 5, B , there was a robust correlation between levels of recombination activity (as measured based on GFP expression) and the number of unique reads of Igh rearrangements obtained on introduction of bicistronic vectors expressing 2 copies of WT or mutant RAG2 protein. A more detailed analysis of V-J rearrangements (Fig 5, C, The activity of each RAG2 variant was determined by at least 3 independent experiments from which the mean value was calculated. PHD, Plant homology domain. R39G-R229Q, and G35A-E437K). Furthermore, the repertoire of Igh rearrangements induced by these 3 vectors revealed reduced diversity (as shown by lower Shannon index) and higher clonality (as indicated by increased Simpson index; Fig 5, D) .
DISCUSSION
In this study we determined the recombination activity of naturally occurring RAG2 mutant proteins and demonstrated that mutations associated with SCID and OS have significantly lower residual activity than mutations detected in patients with less severe clinical presentations (AS and CID-G/AI). Overall, these data confirm that for human RAG2 deficiency, residual activities of the mutations correlate with the severity of the clinical presentation, as previously demonstrated for RAG1 deficiency. 6 Although numbers of both patients and mutations analyzed in our current study for RAG2 deficiency was lower than in our previous study of RAG1 deficiency (79 mutations identified in 63 patients with RAG1 deficiency vs 41 mutations identified in 55 patients with RAG2 deficiency), significant differences in average RAG2 recombination activity were observed in patients presenting with different clinical phenotypes. Specifically, mutations associated with CID-G/AI supported a recombination activity that was significantly greater than that in mutations associated with more severe phenotypes (AS, OS, and SCID). In the case of RAG2-mutated patients, the F62L, T77N, and G451A RAG2 mutations were only found in patients with CID-G/AI. In addition, recurrence of the same low-activity mutations (C41W, R229Q, R229W, and C478Y) in multiple patients presenting with either SCID or OS phenotype could be predictive of a severe clinical phenotype in newly diagnosed patients carrying these mutations.
We have also developed a method whereby use of bicistronic vectors allows us to test the recombination activity of compound heterozygous RAG2 mutations and have shown that this approach is particularly useful in cases in which the 2 mutant alleles exert very different levels of recombination activity. Recently, another method based on a multiple plasmid transfection assay has been published that allows simultaneous testing of RAG variants that have been reported as compound heterozygous changes in patients. 32 Compared with that method, ours has the advantage of equimolar ratios of the 2 RAG2 cDNA variants introduced. In addition, it is flow cytometry based and thus can be scaled up easily to test the activity of multiple pairs of RAG2 variants in a single experiment and permits investigation of RAG activity in a more physiologic genomic context by analyzing rearrangements at the endogenous Igh locus. Overall, use of the bicistronic vector is preferable when faced with compound heterozygous mutations because it allows us to study the net effect of the 2 mutations on the recombination activity of the heterotetrameric RAG complex and might lead to improved correlation with the clinical phenotype, as shown in the case of P9 in this study. However, even with this approach, correlation between in vitro recombination activity and in vivo clinical and immunologic phenotypes is not absolute. In particular, environmental factors, including exposure to microorganisms and use of drugs, have been shown to modulate the phenotype of RAG deficiency in both patients and mice. [33] [34] [35] [36] Nonetheless, functional testing of the recombination activity of newly identified occurring RAG2 variants is important to assess whether these are disease causing. In this study 4 variants (P253R, F386L, N474S, and M502V) were found to support WT levels of recombination activity. One of these variants (M502V) was detected in compound heterozygosity with the S160L variant in patient P12. When tested in combination in a bicistronic vector, the S160L and M502V variants supported robust levels of recombination activity (64.6% of WT).
To further assess possible pathogenicity of the M502V variant, we analyzed its CADD-PHRED score and evaluated its frequency in gnomAD. The latter represents a recent evolution of the Exome Aggregation Consortium database, but compared with that database, it has removed subjects known to be affected by severe pediatric diseases and as such might serve as a useful reference set of allele frequency for severe disease studies. The M502V variant is reported in the gnomAD database with an MAF of 0.0019 (including the presence of 4 homozygous subjects) and has a low CADD-PHRED score of 10.54 (see Table E2 ). Altogether, these data indicate that the M502V variant is nonpathogenic.
Patient P39 with SCID and maternal T-cell engraftment was homozygous for the N474S variant, which also supported WT levels of recombination activity. Although this variant is reported in the gnomAD database with an MAF of 2.5e-5, its CADD-PHRED score is rather low (8.358 ). Furthermore, 2 previous studies analyzed in detail both the expression and function of this variant, demonstrating that it supports efficient V(D)J recombination. 37, 38 Patient P44 was compound heterozygous for the T251I and R229Q variants. Although the latter is a well-known pathogenic variant and supports modest levels of recombination activity (8.9% of WT), the T215I variant was permissive for high levels of recombination (67.2%). The combination of the 2 was also permissive for robust recombination activity (63%) and generation of polyclonal rearrangements at the endogenous Igh locus when introduced into Rag2 2/2 v-Abl pro-B cells by using a bicistronic vector. Furthermore, although the T215I variant has a relatively high CADD-PHRED score of 21.4, it is reported in the gnomAD database with an MAF of 0.002984, although it was as high as 0.02527 in South Asians, including 11 homozygous subjects (10 of whom are from South Asia). Finally, patient P11 with OS was compound heterozygous for the P253R and K440N variants, with 95.4% and 26.7% activity, respectively. Although the P253R variant is not reported in public databases and is scored as possibly damaging by Polyphen-2, 39 the observation that it supports WT levels of recombination activity raises doubts about its possible pathogenicity. According to American College of Medical Genetics and Genomics criteria, both the T215I and the P253R variants are scored as variants of unknown significance, and additional in vitro data and in vivo observations are needed to resolve their pathogenicity.
In summary, we have performed a comprehensive analysis of the recombination activity of naturally occurring RAG2 variants. Our data support the notion that genotype-phenotype correlation exists for this disease, as previously demonstrated for RAG1 deficiency. However, this correlation is not absolute, and other genetic and environmental factors can contribute to determine the clinical phenotype. Notwithstanding this limitation, the flow cytometry-based assay to test the functional activity of RAG1 and RAG2 variants (with use of bicistronic vectors to assess the effects of compound heterozygous variants) might help assess the possible pathogenicity of newly identified RAG variants. This is particularly important because RAG deficiency has emerged as the second most common form of SCID that can be identified by using newborn screening. 40, 41 
